Okafor, Raymond

69-year-old with malignant pleural mesothelioma (epithelioid, BAP1 loss), stage III, completed 4 cycles nivolumab + ipilimumab with stable disease. Evaluate role of cytoreductive surgery (pleurectomy/decortication) after immunotherapy vs. continued systemic therapy. Discuss perioperative risk given prior asbestos-related pleural disease.

Nivolumab + ipilimumab first-line per CheckMate 743 — patient selection and response monitoring.

BAP1 loss as prognostic marker — clinical trial eligibility.

BAP1 loss as prognostic marker — clinical trial eligibility.

Surgical candidacy — EPP vs. P/D with heated intraoperative chemotherapy.

Nivolumab + ipilimumab first-line per CheckMate 743 — patient selection and response monitoring.

Surgical candidacy — EPP vs. P/D with heated intraoperative chemotherapy.

Surgical candidacy — EPP vs. P/D with heated intraoperative chemotherapy.

Nivolumab + ipilimumab first-line per CheckMate 743 — patient selection and response monitoring.

BAP1 loss as prognostic marker — clinical trial eligibility.

Surgical candidacy — EPP vs. P/D with heated intraoperative chemotherapy.